At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 12 target
Drug / intervention
Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cellscombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells for Solid Tumor. Currently recruiting, targeting 12 participants across 1 site.
Detailed Summary
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC729 in the treatment of advanced malignant solid tumors. Condition or disease:advanced malignant solid tumors. Intervention/treatment:Biological: CD70 CAR-NKT cells. Phase:I
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1RecruitingOverdue
20252026
Enrollment StartApr 2024
First PostedMay 2024
Primary CompletionJun 2026
TodayJul 2026
First PostedMay 1, 2024
Enrollment StartApr 11, 2024
Primary CompletionJun 28, 2026
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 2.2 years ago
Interventions
Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cellscombination
Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.